Maxigen Biotech (TPE:1783) Cyclically Adjusted Book per Share: NT$14.32 (As of Dec. 2025)


TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.65
GF Value NT$61.16
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Cyclically Adjusted Book per Share?

Maxigen Biotech TPE:1783 +0.12% 87 Cyclically Adjusted Book per Share is NT$14.32 as of Dec. 2025. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.16 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Maxigen Biotech's adjusted book value per share for the three months ended in Dec. 2025 was NT$17.145. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$14.32 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Maxigen Biotech's average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Maxigen Biotech was 6.50% per year. The lowest was 4.40% per year. And the median was 5.45% per year.

As of today (2026-07-08), Maxigen Biotech's current stock price is NT$40.65. Maxigen Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$14.32. Maxigen Biotech's Cyclically Adjusted PB Ratio of today is 2.84.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Maxigen Biotech was 5.95. The lowest was 2.42. And the median was 3.25.


Maxigen Biotech  (TPE:1783) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Maxigen Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=40.65/14.32
=2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Maxigen Biotech was 5.95. The lowest was 2.42. And the median was 3.25.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Maxigen Biotech Cyclically Adjusted Book per Share Related Terms


Maxigen Biotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Cyclically Adjusted Book per Share Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.37 12.58 13.28 13.72 14.32

Maxigen Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.72 13.95 14.11 14.27 14.32

TPE:1783 vs ISRG, BDX, MDLN: Cyclically Adjusted Book per Share Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cyclically Adjusted PB Ratio falls into.


TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Maxigen Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=17.145/324.0540*324.0540
=17.145

Current CPI (Dec. 2025) = 324.0540.

Maxigen Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201603 9.708 238.132 13.211
201606 9.543 241.018 12.831
201609 9.519 241.428 12.777
201612 9.549 241.432 12.817
201703 9.493 243.801 12.618
201706 9.791 244.955 12.953
201709 9.884 246.819 12.977
201712 9.924 246.524 13.045
201803 10.030 249.554 13.024
201806 10.188 251.989 13.102
201809 10.409 252.439 13.362
201812 10.507 251.233 13.553
201903 10.591 254.202 13.501
201906 10.273 256.143 12.997
201909 10.518 256.759 13.275
201912 10.611 256.974 13.381
202003 10.738 258.115 13.481
202006 10.320 257.797 12.972
202009 10.471 260.280 13.037
202012 10.722 260.474 13.339
202103 10.992 264.877 13.448
202106 11.259 271.696 13.429
202109 12.653 274.310 14.948
202112 12.838 278.802 14.922
202203 13.107 287.504 14.773
202206 13.527 296.311 14.794
202209 14.048 296.808 15.338
202212 14.569 296.797 15.907
202303 15.110 301.836 16.222
202306 14.801 305.109 15.720
202309 15.395 307.789 16.209
202312 15.305 306.746 16.169
202403 15.212 312.332 15.783
202406 14.939 314.175 15.409
202409 14.984 315.301 15.400
202412 15.423 315.605 15.836
202503 16.483 319.799 16.702
202506 15.754 322.561 15.827
202509 16.431 324.800 16.393
202512 17.145 324.054 17.145

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$14.32 mean?
Maxigen Biotech (TPE:1783) has a Cyclically Adjusted Book per Share of NT$14.32 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Maxigen Biotech and its competitors.
Is Maxigen Biotech's Cyclically Adjusted Book per Share too high?
Maxigen Biotech's current Cyclically Adjusted Book per Share is NT$14.32. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Cyclically Adjusted Book per Share compare to ISRG and BDX?
Maxigen Biotech's Cyclically Adjusted Book per Share of NT$14.32 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current Cyclically Adjusted Book per Share is NT$14.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.16, compared to a current price of NT$40.65 — trading 33.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$14.32. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Cyclically Adjusted Book per Share is NT$14.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.65 is trading 33.5% below its estimated GF Value™ of NT$61.16. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Cyclically Adjusted Book per Share: NT$14.32
  • GF Value™: NT$61.16 vs. price of NT$40.65 (33.5% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.65
Price
NT$61.16
GF Value